A statement released earlier today by Wedbush about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) bumps the target price to $13.00
- Updated: September 22, 2016
Wedbush bumped up the target of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $13.00 stating a potential upside of 0.54%.
Boasting a price of $8.44, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded 4.20% higher on the day. With the last stock price close up 0.47% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Achillion Pharmaceuticals, Inc. has recorded a 50-day average of $8.49 and a two hundred day average of $8.40. Volume of trade was up over the average, with 2,036,821 shares of ACHN changing hands over the typical 1,365,310
With a total market value of $0, Achillion Pharmaceuticals, Inc. has price-earnings ratio of 172.24 with a one year low of $5.57 and a one year high of $10.95 .
In addition to Wedbush reporting its target price, a total of 5 firms have issued a report on the stock. The consensus target price is $9.40 with 2 firms rating the stock a strong buy, 1 firm rating the stock a buy, 3 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.